Merck noted that future partnerships with Moderna remain focused on oncology, with the two companies continuing to work together to develop personalized cancer vaccines such as mRNA-4157 as well as cancer vaccines that encode the four most common KRAS mutations. This evidence concerns the gene KRAS and cancer.